An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT01670981

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
Vericel Corporation (from the registry)
Registry
  • NCT NCT01670981
Other papers using this trial's data
  • Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial Lancet (London, England), 2016-06-11 DOI, PubMed 27059887 PubMed links an erratum for this paper. Erratum: PMID 27312309

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01670981. Randomized; quadruple masking; primary purpose treatment. Start 2013-02-20 (actual); primary completion 2016-02-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
Acronym
ixCELLDCM
Condition
Ischemic Dilated Cardiomyopathy (IDCM)
Intervention (Biological)
ixmyelocel-T
Intervention (Other)
Placebo
Lead sponsor
Vericel Corporation (class: industry)

Record details

Record id
cardio:ct-nct01670981
Content hash
a753ef5ebb77da9dc13149174d3180cda5f7a4899c72b72831a75726920f0fb4